42 results about "Micronazole" patented technology

The invention discloses a detection method of a compound preparation containing a compound Zingiber corallinum Hance solution and a urea miconazole ointment. The detection method comprises items of characters, inspection, identification and content determination. The identification comprises a qualitative identification, a thin-layer chromatography identification with a contrast of Zingiber corallinum Hance reference medicine, an efficient liquid chromatography identification with contrasts of a salicylic acid reference substance, a Zingiber corallinum Hance reference substance and a miconazole nitrate reference substance, and a gas chromatography identification with a contrast of a borneol reference substance. The content determination is for determining content of Zingiber corallinum Hance, salicylic acid, borneol, urea and miconazole nitrate in the preparation. The invention is scientific and reasonable, has high accuracy and strong feasibility, improves stability of the compound preparation containing compound Zingiber corallinum Hance solution and urea miconazole ointment, and effectively controls quality of the compound preparation containing compound Zingiber corallinum Hance solution and urea miconazole ointment, thus ensuring clinical efficacy of the compound preparation.

The invention discloses an Acinetobacter ZJPH1806 and its application in the preparation of a chiral intermediate of miconazole. (R)-2-chloro-1 is prepared by asymmetric reduction of 2,2',4'-trichloroacetophenone ‑(2,4‑chlorophenyl)ethanol, the product obtained is of high optical purity. In the pH 7.6 phosphate buffer system, with glycerol as the auxiliary substrate, 2g / L substrate was added to react for 26h, the yield of R-type product was 83.2%, and the e.e. value was >99.9%.

The invention discloses acinetobacter sp. ZJPH1806 and an application thereof to preparation of a miconazole chiral intermediate. 2,2',4'-trichloroacetophenone is subjected to asymmetric reduction toprepare (R)-2-chlorine-1-(2,4-chlorophenyl) ethanol, and obtained products are high in optical purity. In a phosphate buffer liquid system of which the pH is 7.6, glycerine is used as an auxiliary substrate, 2g / L of a substrate is added, a reaction is performed for 26h, the yield of R-type products is 83.2%, and e.e. value is greater than 99.9%.

The present disclosure relates to an improved method for producing ergothioneine, comprising the steps of: (a) inoculating Pleurotus ostreatus strain CGMCC No.6232 into a seed medium, and culturing it to prepare a seed liquor, wherein the seed medium uses soybean cake powder as nitrogen source; and (b) inoculating the seed liquor into a fermentation basal medium, and then culturing it to obtain a fermentation broth of Pleurotus ostreatus mycelia. Further, any one or more members selected from NH4Cl, NH4NO3, NaCl, polyethylene glycol, folic acid, vitamin B1 (VB1), indolebutyric acid, citric acid, pyruvic acid, arginine, lysine, leucine, aspartic acid, glutamic acid, betaine, histidine, cysteine, methionine, tween, span, chitosan, Fluconazole, Miconazole, Ketoconazole, ethylenediaminetetraacetic acid (EDTA), isopropyl alcohol and dimethyl sulfoxide are added into the fermentation basal medium.

Methods of treating infections caused by free-living amoeba are disclosed. The methods generally include systemic administration of an effective amount of miltefosine, such as an oral or intravenous formulation, and optionally local administration of an effective amount of miltefosine, such as a topical formulation of miltefosine. The methods may further include administration of one or more secondary agents. Exemplary secondary agents include steroids, polyhexamethylene biguanide (PHMB), chlorhexidine, propamidine isethionate, dibromopropamidine isethionate, neomycin, paromomycin, polymyxin B, clotrimazole, ketoconazole, miconazole, and itraconazole. The methods may be used to treat patients with infections caused by a free-living amoeba such as Naegleria fowleri, Balamuthia mandrillaris, Sappinia diploidea, and Acanthamoeba species. Exemplary infections include Acanthamoeba keratitis, granulomatous amoebic encephalitis, cutaneous acanthamoebiasis, primary amoebic meningoencephalitis, Sappinia amoebic encephalitis, or a disseminated disease associated with a free-living amoeba.

The invention discloses a children eczema ointment and a preparation method thereof, and belongs to the field of eczema medicines. According to the children eczema ointment provided by the invention,miconazole nitrate can inhibit synthesis of fungal cell membranes and kill fungi, all the medicinal components cooperate with one another to jointly achieve the effects of relieving itching, diminishing inflammation, inhibiting bacteria and killing bacteria, and the ointment particularly has an obvious effect on fungal infection and eczema infection, is safe and non-irritant to use, and is suitable for children to take externally.

The invention relates to the technical field of medicines and discloses a new use of forsythiaside as a synergist of antifungal agents. In vivo and in vitro experiments show that the forsythiaside can be combined with the antifungal agents, such as fluconazole, itraconazole, miconazole, ketoconazole and the like, thereby improving the treatment effect of superficial and deep fungal infection withdifferent degrees, leading the antifungal agents to recover the role to fungi with drug resistance and further using the forsythiaside as the synergist of the antifungal agents. The invention opens up the new use of the forsythiaside, and the use of the forsythiaside as the synergist of the antifungal agents can not only improve the antifungal role of drugs, but also lead the antifungal agents torecover the role to the fungi with drug resistance under the situations that the clinical drug resistance of the fungi is increasingly common and the drug resistance degree is increasingly serious, and further reduce the dosage of the antifungal agents, thereby saving medical expenses for patients and reducing toxicity and side effects of the drugs.

The invention belongs to the field of chemical detection, and in particular relates to a high performance liquid chromatography (HPLC) method for detecting triamcinolone acetonide acetate and miconazole nitrate related substances in Qumixin cream. The method comprises the following steps: (1) testing the chromatographic condition and system suitability; (2) preparing a solution; (3) determining, and the like. The HPLC method for detecting the triamcinolone acetonide acetate and the miconazole nitrate related substances in the Qumixin cream is simple to operate, better in degree of separation,many in detected related substances and high in detection efficiency, and has good specificity, precision and accuracy; compared with the prior art, the method can detect more impurities, and can moreeffectively control the related substances in the Qumixin cream.

Provided are liquid gel and a preparation method thereof. The liquid gel is characterized in that the gel is prepared from 0.5-2.5 parts by weight of chitosan, 0.5-5 parts by weight of hydroxypropyl methylcellulose, 0.5-6 parts by weight of polyethylene glycol 6000, 0.1-0.3 part by weight of chlorhexidine acetate, 0.1-3 parts by weight of carbomer, 0.1-2 parts by weight of propylene glycol, 0.1-3 parts by weight of Chinese hawthorn seeds, 0.2-2 parts by weight of hyaluronic acid matter, 0.01-0.5 part by weight of miconazole nitrate and 50-70 parts by weight of purified water, and the pH ranges from 5 to 7.5. The liquid gel has the advantages of being small in side effect, good in treatment effect, not likely to cause genital tract flora unbalance and capable of effectively relieving or curing the disease.

The invention belongs to the technical field of medicine, and relates to the new application of miconazole and derivatives thereof in treating diseases and diseases of biopathological processes in which TGR5 participates. The structural formulas of the miconazole and its derivatives are as follows. The miconazole and its analogues can activate TGR5 activity, and can be used for treating or preventing diseases related to the regulation of TGR5 activity.

The invention discloses a dermatophytosis preparation. In the dermatophytosis preparation, miconazole nitrate and triclosan are main bactericidal components and can generate a synergistic effect by matched use to enhance a bactericidal effect; urotropin mainly plays roles in convergence and hidroschesis in a formula and simultaneously has a bactericidal effect; hexadecadrol is a corticosteroid drug and mainly plays anti-inflammatory and anti-pruritic roles in the formula; dimethyl sulfoxide mainly plays a solubilizing role in the formula to dissolve the miconazole nitrate and the hexadecadroland simultaneously has a trans-dermal effect to enhance the trans-dermal absorption of the drug and enhance the drug effect; laurocapram is a trans-dermal absorbing agent to enhance the drug trans-dermal absorption function; glycerol is a moisturizing agent and mainly plays roles in moisturizing skin, reducing irritation and increasing drug adhesion in the formula; medical ethanol is mainly used as a solvent and simultaneously has a bactericidal effect; menthol and essence are taken as flavoring agents to improve the drug odor and improve the use experience; the dermatophytosis preparation simultaneously has the effect of covering the foot odor.

Antimicrobial and contraceptive compositions and methods which prevent and / or reduce the risk of transmission of sexually transmitted diseases through sexual activity as well as prevent and / or reduce the risk of pregnancy are provided. The compositions contain (1) a matrix-forming agent, (2) a bio-adhesive agent, (3) a buffering agent, (4) optionally a humectant, (5) optionally a preservative, and (6) water; wherein the composition is suitable for application within the vagina; wherein the compositions forms a semisolid matrix on contact with ejaculate (thereby trapping ejaculated microbes and spermatozoa); wherein the composition causes hardening of cervical mucus (thereby decreasing the probability of sperm entry); wherein the composition forms a bio-adhesive layer over vaginal surfaces (thereby preventing or reducing the risk of contact of STD-causing microbes with the vaginal surfaces); wherein the composition maintains an acidic vaginal pH of less than about 5 in the presence of semen ejaculated from the male; and wherein the composition does not significantly impair the natural microbiological balance within the vagina. The antimicrobial and contraceptive compositions may also contain additional antimicrobial and / or contraceptive agents (e.g., nonoxynol-9, octoxynol-9, benzalkonium chloride, phosphorylated hesperidins, sulfonated hesperidins, polystyrene sulfonates, substituted benzenesulfonic acid formaldehyde co-polymers, H2SO4-modified mandelic acids, povidone iodine, itraconazole, ketoconazole, metronidazole, clotrimazole, fluconazole, teraconazole, miconazole, tinidazole, iconazole, chloramphenicol, nystatin, cyclopiroxolamine, and the like).

The invention belongs to the field of pharmaceutic preparation and relates to a tinidazole / miconazole nitrate / neomycin compound vaginal suppository and a preparation method thereof. The vaginal suppository consists of tinidazole, miconazole nitrate, neomycin sulfate, suppository substrate and an acidifier with curative doses, and can be used for multiple kinds of colpitis. The preparation method comprises the following steps: heating and smelting a suppository substrate and an acidifier with prescription doses; adding fine powders of the tinidazole, the miconazole nitrate and the neomycin sulfate filtered by a 80-mesh sieve into the mixture; quickly stirring the mixture till the mixture is about to be solidified; filling the mixture into a suppository film; and solidifying, scraping, taking out and packaging or directly filling the mixture into a dual-aluminum foil suppository bag. The prepared tinidazole / miconazole nitrate / neomycin compound vaginal suppository has scientific and novel prescription, is directly acted on a pathological part, has high medicament concentration on local parts, overcomes the gastrointestinal upset caused by oral administration, is convenient for patients to use, improves the treatment effect and reduces the toxicity and side effect. The preparation process is simple, has no special requirement on preparation environment, has low cost and stable quality of products and is suitable for industrialized mass production.

The invention discloses an application of an azole compound in preparation of an aldehyde ketone reductase AKR7 synergist. According to the invention, the enzyme activity condition of a metabolic substrate succinic acid semialdehyde (SSA) of human AKR7A2 in the presence or absence of five azole compounds is compared, and the AKR7A2 is an A2 member of an aldehyde keto reductase 7 family. It is shown that posaconazole, ketoconazole, miconazole, voriconazole and itraconazole have the effect of remarkably enhancing the enzyme activity of AKR7A2, and meanwhile posaconazole also has the effect of remarkably enhancing the enzyme activity of AKR7A3 and AKR7A5. Wherein posaconazole, voriconazole and itraconazole are oral administration or injection medicines, and can play a role in enhancing the activity of AKR7 aldoketoreductase 7 family enzymes in vivo.